BGC vs CME
BGC and CME side by side, both in security & commodity brokers, dealers, exchanges & services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BGC and CME compare
CME is the larger company, worth 21 times as much as BGC ($114B against $5.3B).
On earnings, BGC is cheaper: it trades at 22.7× trailing earnings, against 26.1× for CME.
BGC grew revenue faster over the last twelve months (22.9% versus 9.0% for CME).
Both pay dividends: BGC yields 0.72% and CME 3.6%.
BGC scores higher on the StockData Score (17 against 9 for CME), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BGC | CME |
|---|---|---|
| Size and price | ||
| Market cap | $5.3B | $114B |
| Share price | $11.14 | $317.97 |
| Change, 1 year | 21.9% | 13.7% |
| Change, 5 years | 140% | 42.4% |
| Beta (5Y) | 1.01 | 0.36 |
| Employees | 4,560 | 3,875 |
| StockData Score | ||
| Total score | 17 (better) | 9 |
| Valuation score | 4 (better) | 0 |
| Growth score | 4 (better) | 1 |
| Performance score | 4 (better) | 2 |
| Health score | 2 | 5 (better) |
| Dividend score | 3 (better) | 1 |
| Valuation | ||
| P/E | 22.7× (better) | 26.1× |
| P/S | 1.6× (better) | 16.3× |
| P/B | 4.9× | 4.3× (better) |
| EV/EBITDA | 14.5× (better) | 24.4× |
| P/FCF | 9.6× (better) | 26.3× |
| PEG | 0.68 (better) | 1.78 |
| FCF yield | 10.4% (better) | 3.8% |
| Fair value | $13.08 | $262.19 |
| Margin of safety | 14.9% (better) | −21.3% |
| Growth | ||
| Revenue growth (TTM) | 22.9% (better) | 9.0% |
| Revenue growth, 5Y average | 7.4% (better) | 6.0% |
| Net income growth (TTM) | 49.5% | – |
| EPS growth (TTM) | 48.5% (better) | 18.1% |
| EPS growth, 5Y average | 20.9% (better) | 13.7% |
| Profitability | ||
| Operating margin | – | 65.7% |
| Net margin | 7.1% | – |
| FCF margin | 16.3% | 62.1% (better) |
| Return on equity | 23.6% | – |
| Return on invested capital | – | 14.1% |
| Financial health | ||
| Debt / equity | 1.63 (better) | 0.00 |
| Net debt / EBITDA | 2.15 | – |
| Current ratio | – | 1.02 |
| Altman Z-score | 1.12 (better) | 0.59 |
| Piotroski F-score | 5 | 5 |
| Dividends and buybacks | ||
| Dividend yield | 0.72% | 3.6% (better) |
| Payout ratio | 15.9% | – |
| Years of dividend growth | 2 (better) | 0 |
| Dividend growth, 5Y average | −14.0% | −3.3% (better) |
| Buyback yield | 5.7% | – |
| Shareholder yield | 6.5% (better) | 3.6% |
| Ownership | ||
| Held by institutions | 65.4% | 90.0% |
| Held by insiders | 48.6% | 0.34% |
| Insider net buying, 12 months | −$95.5K (better) | −$33.6M |
| Superinvestors holding | – | 5 |
| Short interest, % of float | 3.8% | 1.5% |
Go deeper
- BGC stock overview
- BGC income statement
- BGC valuation and score
- CME stock overview
- CME income statement
- CME valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.